<DOC>
	<DOCNO>NCT00017537</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient metastatic recurrent cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Recurrent Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine optimum biologic dose MVF-HER-2 ( 628-647 ) -CRL 1005 vaccine induce anti-HER-2 antibody patient metastatic recurrent cancer . II . Characterize nature severity toxicity drug patient . III . Document clinical response drug patient . OUTLINE : This dose-escalation study . Patients receive MVF-HER-2 ( 628-647 ) -CRL 1005 vaccine intramuscularly day 1 29 . Cohorts 5 patient receive escalate dos MVF-HER-2 ( 627-647 ) -CRL 1005 vaccine least 2 5 patient experience dose-limiting toxicity . Patients follow day 43 57 every 2 month least 1 year . PROJECTED ACCRUAL : Approximately 5-25 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic and/or recurrent solid tumor , especially follow : Breast Ovarian Nonsmall cell lung cancer Gastric adenocarcinoma No standard therapy available No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL ALT le 2 time upper limit normal No hepatitis A , B , C Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No serious cardiopulmonary disorder No congestive heart failure No symptomatic coronary artery disease No serious cardiac arrhythmia Pulmonary : No serious cardiopulmonary disorder No symptomatic chronic obstructive pulmonary disease Immunologic : Reactive least 1 follow skin test antigen : Candida , mumps , Trichophyton , intermediate strength PPD , tetanus toxoid No concurrent disease require corticosteroid immunosuppressive drug No autoimmune disease , include rheumatoid arthritis , systemic lupus erythematosus , scleroderma , polymyositisdermatomyositis , vasculitic syndrome No prior anaphylactic response vaccine No hypersensitivity MVFHER2 ( 628647 ) Other : No active HIV No active infection require antibiotic therapy No serious medical disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : At least 4 week since prior cytotoxic chemotherapy recover Endocrine therapy : At least 4 week since prior hormonal therapy recover No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : At least 4 week since prior surgery recover No prior splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>